Fosaprepitant (MK-0517): A neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting

Expert Opinion on Investigational Drugs

Volumn 16, Issue 12, 2007, Pages 1977-1985

  Navari, Rudolph M ^a,b,c  

^a Department of Medicine ^*  (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

Aprepitant; Chemotherapy induced nausea and vomiting; Fosaprepitant; Neurokinin 1 receptor antagonist

Indexed keywords

2 [1 [3,5 BIS(TRIFLUOROMETHYL)PHENYL]ETHOXY] 3 (4 FLUOROPHENYL) 4 (3 OXO 1 PHOSPHORYL 1,2,4 TRIAZOL 5 YLMETHYL)MORPHOLINE; 3 (2 METHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; ANTHRACYCLINE; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; APREPITANT; BENZODIAZEPINE DERIVATIVE; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DILTIAZEM; DOXORUBICIN; FOSAPREPITANT; GRANISETRON; METHYLPREDNISOLONE; MIDAZOLAM; MK 0517; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; ONDANSETRON; ORAL CONTRACEPTIVE AGENT; PLACEBO; SEROTONIN 3 ANTAGONIST; SUBSTANCE P; SUBSTANCE P ANTAGONIST; UNCLASSIFIED DRUG; VOFOPITANT; WARFARIN; MORPHOLINE DERIVATIVE;

ANOREXIA; ANTICIPATORY NAUSEA AND VOMITING; ANTIEMETIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BIOEQUIVALENCE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; DIARRHEA; DRUG ABSORPTION; DRUG BINDING; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SOLUBILITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HEADACHE; HICCUP; HUMAN; MONOTHERAPY; NAUSEA; NAUSEA AND VOMITING; NONHUMAN; PATHOPHYSIOLOGY; RISK FACTOR; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; VOMITING; ANIMAL; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DRUG ANTAGONISM; PHYSIOLOGY; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MORPHOLINES; NAUSEA; RECEPTORS, NEUROKININ-1; VOMITING;

EID: 39549115523     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.12.1977     Document Type: Article

References (41)

1. COHEN L, DE MOOR CA, EISENBERG P, MING EE, HU H: Chemotherapy-induced nausea and vomiting - incidence and impact on patient quality of life at community oncology settings. Support. Care Cancer (2007) 15(5):497-503.
2. BLOECHL-DAUM B, DEUSON RR, MAVROS P, HANSEN M, HERRSTEDT J: Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J. Clin. Oncol. (2006) 24:4472-4478.
3. GRALLA RJ, DE WIT R, HERRSTEDT J et al.: Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials. Cancer (2005) 104:864-868.
4. SCHWARTZBERG L: Chemotherapy-induced nausea and vomiting: state of the art in 2006. J. Support. Oncol. (2006) 4(2 Suppl. 1):3-8.
5. GRUNSBERG SM, OSOBA D, HESKETH PJ et al.: Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity - an update. Support. Care Cancer (2005) 13:80-84.
6. MITCHELL EP: Gastrointestinal toxicity of chemotherapeutic agents. Semin. Oncol. (1992) 19:566-579.
7. GUYTON AC, HALL JE: Physiology of gastrointestinal disorders. In: Textbook of Medical Physiology. Elsevier Saunders, Philadelphia, USA (2006):823-824.
8. PASRICHA JP: Drugs affecting gastrointestinal function. In: Goodman & Gilman's The Pharmacological Basis of Therapeutics. Hardman JG, Limbird LE (Eds), McGraw-Hill, New York, USA (2001):1000-1005.
9. BAKER PD, MORZORATI SL, ELLETT ML: The pathophysiology of chemotherapy-induced nausea and vomiting. Gastroenterol. Nurs. (2005) 28:469-480.
10. KRIS MG, ROILA F, DE MULDER PH, MARTY M: Delayed emesis following anticancer chemotherapy. Support. Care Cancer (1998) 6:228-232.
11. TAVORATH R, HESKETH PJ: Drug treatment of chemotherapy-induced delayed emesis. Drugs (1996) 52:639-648.
12. ROILA F, HESKETH PJ, HERRSTEDT J: Antiemetic subcommittee of the multinational association of supportive care in cancer. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia international antiemetic consensus conference. Ann. Oncol. (2006) 17:20-28.
13. KRIS MG, HESKETH PJ, SOMERFIELD MR et al.: American society of clinical oncology guideline for antiemetics in oncology: update 2006. J Clin. Oncol. (2006) 24:2932-2947.
14. COCQUYT V, VAN BELLE S, REINHARDT RR et al.: Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur. J. Cancer (2001) 37:835-842.
15. VAN BELLE S, LIECHINITSER M, NAVARI RM et al.: Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-0869. Cancer (2002) 94:3032-3041.
16. LASSETER KC, GAMBALE J, JIN B et al.: Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. J. Clin. Pharmacol. (2007) 47:834-840.
17. DIEMUNSCH P, GRELOT L: Potential of substance P antagonists as antiemetics. Drugs (2000) 60:533-546.
18. WATSON JW, GONSALVES SF, ROSSA AA et al.: The antiemetic effects of CP-99,994 in the ferret and dog: role of the NK-1 receptor. Br. J. Pharmacol. (1998) 115:84-94.
19. BERGSTRÖM M, FASTH KJ, KILPATRICK G et al.: Brain uptake and receptor binding of two [C11] labeled selective high affinity NK-1 antagonists GR203040 and GR205171 - PET studies in rhesus monkey. Neuropharmacology (2000) 39:664-670.
20. TATTERSALL FD, RYCROFT W, FRANCIS B et al.: Tachykinins NK-1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets. Neuropharmacology (1996) 35:1121-1129.
21. MINAMI M, ENDO T, YOKODA H et al.: Effects of CP-99,994, a tachykinin NK-1 receptor antagonist, on abdominal afferent vagal activity in ferrets: evidence for involvement of NK-1 and 5-HT3 receptors. Eur. J. Pharmacol. (2001) 428:215-220.
22. HARGREAVES R: Imaging substance P receptors (NK1) in the living human brain using positron emission tomography. J. Clin. Psychiatry (2002) 63(Suppl. 11):18-24.
23. TATTERSALL FD, RYCROFT W, CUMBERBATCH M et al.: The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets. Neuropharmacology (2000) 39:652-663.
24. BLUM RA, MAJURNDAR AK, MCCREA JB et al.: Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin. Ther. (2003) 25:1407-1419.
25. FEURING M, LEE Y, ORLOWSKI LH et al.: Lack of effect of aprepitant on digoxin pharmacokinetics in healthy subjects. J. Clin. Pharmacol. (2003) 43:912-917.
26. MCCREA JB, MAJURNDAR AK, GOLDBERG MR et al.: Effects of the neurokinin-1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin. Pharmacol. Ther. (2003) 74:17-24.
27. MAJURNDAR AK, MCCREA JB, PANEBIANCO DL et al.: Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. Clin. Pharmacol. Ther. (2003) 74:150-156.
28. NAVARI RM, REINHARDT RR, GRALLA RJ et al.: Reduction of cisplatin-induced emesis by a selective neurokinin-1 receptor antagonist. N. Engl. J. Med. (1999) 340:190-195.
29. CAMPOS D, PEREIRA JR, REINHARDT RR et al.: Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J. Clin. Oncol. (2001) 19:1759-1767.
30. CHAWLA SP, GRUNBERG SM, GRALLA RJ et al.: Establishing the dose of the oral NK-1 antagonist aprepitant for chemotherapy induced nausea and vomiting. Cancer (2003) 97:2290-2300.
31. HESKETH PJ, GRUNBERG SM, GRALLA RJ et al.: The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 study group. J. Clin. Oncol. (2003) 21:4112-4119.
32. POLI-BIGELLI S, RODRIGUES-PEREIRA J, CARIDES AD et al.: Addition of the neurokinin-1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Cancer (2003) 97:3090-3098.
33. DE WITT R, HERRSTEDT J, RAPOPORT BL et al.: Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J. Clin. Oncol. (2003) 21:4105-4111.
34. DE WITT R, HERRSTEDT J, RAPOPORT B et al.: The oral NK-1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomized, placebo-controlled Phase III clinical trials. Eur. J. Cancer (2004) 40:403-410.
35. WARR DG, HESKETH PJ, GRALLA RJ et al.: Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J. Clin. Oncol. (2005) 23:2822-2830.
36. NAVARI RM, CARIDES AD, GERTZ BJ: Prevention of cisplatin-induced emesis by a neurokinin-1 receptor antagonist. N. Engl. J. Med. (1999) 340:1926.
37. NAVARI RM: Overview of the updated antiemetic guidelines for chemotherapy-induced nausea and vomiting. Community Oncol. (2007) 4(Suppl. 1):1-11.
38. GRUNBERG SM, DEUSON R, MAVROS P et al.: Incidence of chemotherapy-induced nausea and emesis after modern antiemetics: perception versus reality. Cancer (2004) 100:2261-2268.
39. KRIS MG: Why do we need another antiemetic? J. Clin. Oncol. (2003) 21:4077-4080.
40. FABI A, BARDUAGNI M, LAURO S et al.: Is delayed chemotherapy-induced emesis well managed in oncological clinical practice? An observational study. Support. Care Cancer (2003) 11:156-161.
41. NAVARI RM, PROVINCE PS: Emerging drugs for chemotherapy-induced emesis. Expert Opin. Emerg. Drugs (2006) 11(1):137-151.